Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Turcot syndrome 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 5Nivolumab 3durvalumab 2atezolizumab 2relatlimab 1fludarabine phosphate 1fludarabine 1denileukin diftitox 1danvatirsen 1avelumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Irinotecan 1Immunoglobulin G 1Immune Checkpoint Inhibitors 1IMM-101 1E7777 fusion protein 1Docetaxel 1Disulfides 1Diffusion Tensor Imaging 1Cyclophosphamide 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Turcot syndrome × denileukin diftitox × Clear all
NCT05200559 2026-05-29

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

University of Pittsburgh

Phase 1/2 Active not recruiting
25 enrolled
Gynecologic

Turcot syndrome, Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡